This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.
Male or female aged 18-70 years
Diagnosis of AML, ALL, MDS, CML, NHL, HD, CLL requiring AHSCT
Has an HLA-matched related (MRD), HLA-matched unrelated (MUD), haploidentical (HAPLO) or 1-Ag mismatched unrelated donor (MMUD)
Karnofsky performance >70%
Inability to comply with medical recommendations or follow-up
Pregnancy
Active/uncontrolled bacterial or viral infection (PI is the final arbiter of this criterion.)
Has active CNS or ocular disease involvement within 3 months
University of California, Irvine
Lead sponsor